Chronic Disorder Trends Will Expand Noninvasive Neuromodulation Adoption

Published
06 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$21.40
75.5% undervalued intrinsic discount
15 Aug
US$5.24
Loading
1Y
-14.2%
7D
13.3%

Author's Valuation

US$21.4

75.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 29%

Shared on24 Apr 25
Fair value Decreased 29%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 10%

AnalystConsensusTarget has decreased revenue growth from 32.8% to 28.0%, decreased profit margin from 29.9% to 12.9%, increased future PE multiple from 12.5x to 36.2x and decreased shares outstanding growth rate from 0.2% to 0.1%.